The Health Impact Fund: incentives for improving access to medicines

The Lancet

Volumn 375, Issue 9709, 2010, Pages 166-169

  Banerjee, Amitava ^a   Hollis, Aidan ^c   Pogge, Thomas ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; FUNDING; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; PATENT; PRIORITY JOURNAL;

EID: 73449091537     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61296-4     Document Type: Note

References (21)

1. Global Poverty Report. Okinawa Summit (July 2000). http://www.adb.org/Documents/Reports/Global_Poverty/2000/G8_2000.pdf (accessed July 3, 2009).
2. Chen S., and Ravallion M. The developing world is poorer than we thought, but no less successful in the fight against poverty. World Bank Policy Research Working Paper WPS 4703, 2008: 34. http://econ.worldbank.org/docsearch (accessed July 3, 2009).
3. A gateway to the UN System's work on the MDGs. United Nations Millennium Development Goals. http://www.un.org/millenniumgoals/ (accessed July 3, 2009).
4. Von Schirding Y. The World Summit on Sustainable Development: reaffirming the centrality of health. Global Health 1 (2005) 8
5. Witty A. Big pharma as a catalyst for change. February 13, 2009 Speech to Harvard Medical School. http://www.gsk.com/media/Witty-Harvard-Speech-Summary.pdf (accessed July 3, 2009).
6. The Lancet. Pharmaceuticals, patents, publicity...and philanthropy?. Lancet 373 (2009) 693
7. Garber A.M. An uncertain future for cardiovascular drug development?. N Engl J Med 360 (2009) 1169-1171
8. WHO. The world drug situation (1988), World Health Organization, Geneva
9. WHO. Chronic Diseases Report 2005. Chapter 2: chronic diseases and poverty (2005), World Health Organization, Geneva
10. Gemmill M.C., Costa-Font J., and McGuire A. In search of a corrected prescription drug elasticity estimate: a meta-regression approach. Health Econ 16 (2007) 627-643
11. Trade-related aspects of intellectual property rights agreement. World Trade Organization. http://www.wto.org/English/tratop_e/TRIPS_e/trips_e.htm (accessed July 3, 2009).
12. Attaran A., and Gillespie-White L. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa. JAMA 286 (2001) 1886-1892
13. Oliveira M.A., Bermudez J.A., Chaves G.C., and Velásquez G. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?. Bull World Health Organ 82 (2004) 8150-8221
14. Attaran A. How do patents and economic policies affect access to essential medicines in developing countries?. Health Affairs (Millwood) 23 (2004) 155-166
15. Hollis A., and Pogge T. The Health Impact Fund. Making new medicines accessible for all (2008), Incentives for Global Health. http://www.healthimpactfund.org (accessed July 3, 2009).
16. Tunis S.R., Stryer D.B., and Clancy C.M. 2003. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290 (2003) 1624-1632
17. In: Baciu A., Stratton K., and Burke S.P. (Eds). The future of drug safety: promoting and protecting the health of the public, 2007 (2007), National Academies Press, Washington, DC
18. Scandinavian Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
20. Hollis A. A comprehensive advanced market commitment (2007). Submission to World Health Organization public hearing on public health, innovation and intellectual property. http://www.who.int/phi/public_hearings/second/contributions_section2/Section2_Aidan_Hollis_Full_Contribution.pdf (accessed July 3, 2009).
21. Horton R. WHO: the casualties and compromises of renewal. Lancet 359 (2002) 1605-1611